Potential consolidation therapies for Hodgkin’s Lymphoma patients
Dr Anna Sureda from the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain discusses the standard of care for Hodgkin’s Lymphoma and potential consolidation therapies. Most patients with Hodgkin’s Lymphoma are cured with first-line chemotherapy however, a small proportion of patients are non-responders or relapse, who have to undergo an autologous stem cell transplant. However, approximately 50% of patients relapse after transplantation. As a result, drugs are being tested to improve the rate of relapse after second-line treatment, and one study demonstrated a reduction in relapse rates after receiving a monoclonal antibody as consolidation therapy. Recorded at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France.
Get great new content delivered to your inboxSign up